Total Payments
$7,082
2024 Payments
$255.06
Companies
9
Transactions
44
Medicare Patients
14,925
Medicare Billing
$630,136
Payment Breakdown by Category
Other$5,900 (83.3%)
Food & Beverage$1,124 (15.9%)
Education$51.00 (0.7%)
Travel$6.68 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,900 | 7 | 83.3% |
| Food and Beverage | $1,124 | 34 | 15.9% |
| Education | $51.00 | 1 | 0.7% |
| Travel and Lodging | $6.68 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $6,242 | 17 | $0 (2019) |
| Merck Sharp & Dohme LLC | $268.32 | 10 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $259.97 | 8 | $0 (2024) |
| ABBVIE INC. | $151.70 | 4 | $0 (2024) |
| Insmed, Inc. | $95.66 | 1 | $0 (2019) |
| Gilead Sciences, Inc. | $18.57 | 1 | $0 (2024) |
| BioFire Diagnostics, LLC | $17.94 | 1 | $0 (2017) |
| bioMerieux Inc | $14.03 | 1 | $0 (2023) |
| Nabriva Therapeutics, plc | $13.61 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $255.06 | 10 | ABBVIE INC. ($151.70) |
| 2023 | $29.34 | 2 | Paratek Pharmaceuticals, Inc. ($15.31) |
| 2022 | $51.00 | 1 | Paratek Pharmaceuticals, Inc. ($51.00) |
| 2021 | $130.94 | 2 | Paratek Pharmaceuticals, Inc. ($130.94) |
| 2020 | $13.61 | 1 | Nabriva Therapeutics, plc ($13.61) |
| 2019 | $231.62 | 3 | Insmed, Inc. ($95.66) |
| 2018 | $12.32 | 1 | Merck Sharp & Dohme Corporation ($12.32) |
| 2017 | $6,358 | 24 | Allergan Inc. ($6,181) |
All Payment Transactions
44 individual payment records from CMS Open Payments — Page 2 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/29/2017 | BioFire Diagnostics, LLC | FilmArray (Device) | Food and Beverage | Cash or cash equivalent | $17.94 | General |
| Category: Clinical Diagnostics | ||||||
| 10/26/2017 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/26/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $105.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/09/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug), ZEPATIER | Food and Beverage | In-kind items and services | $11.35 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/26/2017 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/26/2017 | Allergan Inc. | DALIRESP (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: RESPIRATORY | ||||||
| 07/11/2017 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/10/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $10.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/31/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug), ZINPLAVA | Food and Beverage | In-kind items and services | $12.29 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/22/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/11/2017 | Allergan Inc. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/10/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/03/2017 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Food and Beverage | In-kind items and services | $88.16 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/19/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug) | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/22/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug), DIFICID, ZINPLAVA | Food and Beverage | In-kind items and services | $10.79 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/15/2017 | Merck Sharp & Dohme Corporation | CUBICIN RF (Drug), ZERBAXA, SIVEXTRO | Food and Beverage | In-kind items and services | $9.71 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/08/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/01/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug) | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 151 | 271 | $70,435 | $23,641 |
| 2022 | 8 | 466 | 748 | $195,210 | $68,194 |
| 2021 | 12 | 13,895 | 14,160 | $616,257 | $462,508 |
| 2020 | 6 | 413 | 635 | $211,552 | $75,792 |
Total Patients
14,925
Total Services
15,814
Medicare Billing
$630,136
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 115 | $18,692 | $7,000 | 37.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 69 | $16,098 | $6,129 | 38.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 16 | 36 | $17,460 | $5,550 | 31.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 28 | $12,722 | $3,593 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 23 | $5,463 | $1,369 | 25.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 48 | 104 | $50,440 | $17,676 | 35.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 88 | 97 | $44,038 | $14,593 | 33.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 123 | 243 | $39,366 | $13,531 | 34.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 81 | 149 | $34,717 | $11,917 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 39 | 66 | $15,642 | $5,822 | 37.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 22 | $6,732 | $2,325 | 34.5% |
| 0003A | Adm sarscov2 30mcg/0.3ml 3rd | Office | 2022 | 38 | 38 | $1,520 | $1,448 | 95.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 28 | 29 | $2,755 | $882.39 | 32.0% |
| 0002A | Adm sarscov2 30mcg/0.3ml 2nd | Office | 2021 | 6,077 | 6,085 | $233,180 | $222,622 | 95.5% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 6,190 | 6,223 | $150,380 | $130,699 | 86.9% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 813 | 813 | $32,520 | $31,301 | 96.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 66 | 123 | $59,655 | $21,066 | 35.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 99 | 103 | $46,762 | $16,336 | 34.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 126 | 203 | $32,886 | $11,557 | 35.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 83 | 141 | $32,853 | $11,453 | 34.9% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 154 | 155 | $5,850 | $5,569 | 95.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 37 | 63 | $14,931 | $5,337 | 35.7% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 170 | 171 | $4,040 | $3,490 | 86.4% |
| 0013A | Fee covid-19 vac 2 booster | Office | 2021 | 56 | 56 | $2,240 | $2,156 | 96.3% |
| 0031A | Adm sarscov2 vac ad26 .5ml | Office | 2021 | 24 | 24 | $960.00 | $924.00 | 96.3% |
About Rutul Dalal
Rutul Dalal is a Infectious Disease healthcare provider based in Williamsport, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/21/2008. The National Provider Identifier (NPI) number assigned to this provider is 1689824138.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Rutul Dalal has received a total of $7,082 in payments from pharmaceutical and medical device companies, with $255.06 received in 2024. These payments were reported across 44 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($5,900).
As a Medicare-enrolled provider, Dalal has provided services to 14,925 Medicare beneficiaries, totaling 15,814 services with total Medicare billing of $630,136. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Williamsport, PA
- Active Since 09/21/2008
- Last Updated 05/24/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1689824138
Products in Payments
- DALVANCE (Drug) $6,076
- AVYCAZ (Drug) $277.84
- NUZYRA (Drug) $259.97
- Arikayce (Drug) $95.66
- ZERBAXA (Drug) $88.16
- PIFELTRO (Drug) $74.96
- ISENTRESS (Drug) $38.02
- DIFICID (Drug) $24.61
- TEFLARO (Drug) $23.83
- PREVYMIS (Drug) $22.07
- Veklury (Drug) $18.57
- FilmArray (Device) $17.94
- DALIRESP (Drug) $16.21
- Xenleta (Drug) $13.61
- NOXAFIL (Drug) $10.79
- CUBICIN RF (Drug) $9.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.